GeneDx Holdings Corp. Class A Common Stock Earnings Recaps
Q1 2026
May 7, 2026
Shares plunged 47.2% following GeneDx Holdings' earnings release, driven by a significant revenue shortfall mainly due to lower-than-expected reimbursement rates and underperformance in non-core businesses, prompting a downward revision of full-year guidance.
Key takeaways
- Q1 test volume grew 34% year-over-year, indicating strong market demand and early growth in expansion markets.
- Total revenue missed expectations by $12 million, attributed to a $5.5 million shortfall from lower blended average reimbursement rates and a $6.5 million shortfall in non-core businesses.
- Full-year revenue guidance was lowered to a range of $475 million to $490 million, reflecting ongoing challenges in reimbursement and softer contributions from Fabric and biopharma segments.
- Gross margins are expected to hold near 70%, with commitments to return to adjusted profitability in 2026 and significant profitability growth anticipated in 2027.
- The company is focusing resources on core diagnostic offerings and international expansion of the Fabric business, while biopharma sales cycles remain elongated, delaying expected revenue ramp.
Q3 2025
Oct 28, 2025
GeneDx's Q3 2025 results showcase robust financial performance with record growth, prompting an upward revision of revenue guidance to $425-$428 million for the year, supported by increased commercialization efforts and key executive hires.
Key takeaways
- Revenue growth remains strong with ongoing profitability, reflecting effective execution of the company’s strategic initiatives.
- FDA granted breakthrough device designation for ExomeDx and GenomeDx, solidifying GeneDx's leadership in rare disease diagnostics.
- Plans to nearly double the sales force to enhance penetration in pediatrician markets, with a focus on driving adoption of genomic testing.
- Continued expansion into under-penetrated NICU markets, with a goal to significantly scale genetic testing in critical care settings.
- Active involvement in innovative newborn screening initiatives underlines GeneDx’s commitment to proactive, equitable healthcare solutions.
Q2 2025
Aug 2, 2025
GeneDx reported record revenue exceeding $100 million in Q2 2025, driven by robust growth in its core genetic testing services and strategic expansions into new clinical markets.
Key takeaways
- Achieved over $100 million in revenue for the first time in a single quarter, highlighting strong business momentum.
- Captured nearly one-third of pediatric neurologists as new exome and genome ordering providers, indicating deepening market penetration.
- Initiated outreach to pediatric immunologists and expanded into the NICU, targeting a $1 billion opportunity with rapid genomic testing.
- Positioned well for growth following new AAP guidelines allowing pediatricians to utilize genomic sequencing as a first-tier test for developmental delays, potentially transforming the pediatric health landscape.
- Emphasized competitive edge through a unique data set and advanced AI-driven testing capabilities, reinforcing GeneDx’s market leadership in genetic diagnostics.